Blume-Jensen Peter sold ACRV
August 18, 2026 · Form 4 insider transaction
Blume-Jensen Peter sold 484 shares of Acrivon Therapeutics, Inc. at $2.01 per share, a transaction worth $972.84. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Disposed (sell-side)
Shares
484
Price
$2.01
Total value
$972.84
InsiderBlume-Jensen Peter
RoleOfficer, Director
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateAugust 18, 2026
Filing dateAugust 20, 2026
Shares owned after385,859
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.; These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.